Inspire Medical Systems, Inc.
Inspire Medical Systems Reports Q1 2025 Results with 23% Revenue Growth and $0.10 Earnings Per Share
Summary
Inspire Medical Systems, Inc. announced its financial results for the first quarter of 2025, reporting a 23% increase in revenue to $201.3 million compared to the same period last year. The company achieved an earnings per share of $0.10, improved its gross margin to 84.7%, and surpassed 100,000 patients receiving Inspire therapy. Inspire also updated its full-year 2025 guidance, raising diluted net income per share guidance to between $2.20 to $2.30. The company will be participating in various meetings with investors and analysts in May and June 2025.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement